Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Long Term Safety Trial of Spesolimab Treatment in Patients With Crohn's Disease Who Have Completed Previous Spesolimab Trials

NCT04362254 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04362254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04362254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Long Term Safety Trial of Spesolimab Treatment in Patients With Crohn's Disease Who Have Completed Previous Spesolimab Trials
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Terminated
Start date
May 15, 2020
Completion date
September 23, 2022
Enrollment
12 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease